top of page
피펫 샘플

Research Interest in Our Lab

It is becoming evident that microbiota can directly signal to the host by generating bioactive metabolites, which would contribute to the development (i.e., imidazole propionate) or amelioration of metabolic diseases (i.e., short-chain fatty acids). In our lab, we aim to identify therapeutics for metabolic diseases including diabetes and cancer based on mechanistic understanding of the role of microbial metabolites. In addition, we will investigate inter-individual variations or failure in drug response in the context of microbial metabolite milieu by using organoids as a model system.


1. Mechanistic Understanding of the Impacts of Microbial Metabolites on Personalized Responses to Metabolic Interventions

2. Understanding the Impacts of Microbial Regulation of Small Intestine in Host Metabolism by Using Intestinal Organoids

3. Development of Personalized POST-Biotics based on Microbial Metabolites

Better and Safer Therapeutics for Metabolic Diseases Based on Mechanistic Understanding of the Role of Microbial Metabolites

From Association to Causality: the Role of the Gut Microbiota and Its Functional Products on Host Metabolism
 Molecular Cell. 2020. 05. 21
Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1
Cell. 2018.11.01
From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites
Cell. 2016. 06. 02 

Representative Articles

Microbial Imidazole propionate Affects Responses to Metformin through p38g-Dependent Inhibitory AMPK Phosphorylation
 Cell Metabolism. 2020. 10.06
bottom of page